About Schistosomiasis

Schistosomiasis is a parasite carried by snails and transmitted through contact with contaminated fresh water sources such as lakes, ponds, rivers and dams. Schistosomiasis infection is readily transmissible for those who come in frequent contact with contaminated water – particularly children who wade or play in water and women conducting domestic chores.

Project Status

In collaboration with researchers at the James Cook University and The George Washington University, a promising new antigen, Sm-TSP-2 (Schistosoma mansoni Tetraspanin-2), was selected for development as a schistosomiasis vaccine. Then at Texas Children's Hospital and Baylor College of Medicine, Sabin and its partners developed the process for manufacture of the vaccine under cGMP, and was followed by technology transfer to Sabin's manufacturing partner, Aeras.

Schistosomiasis Vaccine

Schistosomiasis afflicts over 200 million people around the globe and is the deadliest disease among the seven most prevalent NTDs, killing an estimated 280,000 people annually. Thanks to private donations from Mr. Morton Hyman, Dr. Gary Michelson, Texas Children’s Hospital and the Blavatnik Family Foundation, the Schistosomiasis Vaccine Initiative (SVI) utilizes and leverages the Sabin Vaccine Institute PDP’s existing programmatic and technical infrastructure to produce and evaluate a schistosomiasis vaccine.

History

The suffering caused by hookworm is not well known in the developed world but in many countries it is all too prevalent. More than 700 million people are infected with hookworm. The largest number of cases occur in impoverished areas of Sub-Saharan Africa, Southeast Asia, China and Latin America. Globally, approximately 3.2 billion people are at risk for hookworm infection.

About Hookworm

Hookworm is an intestinal parasite most commonly found in tropical and sub-tropical climates of Africa, Asia and Latin America.  Hookworm, one of three members of a family of parasites known as the soil-transmitted helminths (STHs), are half-inch long worms that attach themselves to the intestinal wall and feed on human blood. Left untreated, hookworm causes severe intestinal blood loss leading to iron-deficiency anemia and protein malnutrition, particularly in pregnant women and children.

Project Status

 
The Human Hookworm Vaccine Initiative (HHVI) has identified and produced several candidates for potential use as a vaccine. HHVI is focused on developing and testing a vaccine to prevent moderate to severe hookworm infection in children younger than 10 years old living in endemic areas.

Partners

The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:

Capabilities

With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:

Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.

Pages

Subscribe to RSS - Sabin Vaccine Development